Table 2.

FARPRESTO biomarkers

Clinical	Family history Tobacco use Alcohol use Toxic substances exposure Motor symptoms (UPDRS III/MDSUPDRS III) Physical activity Hyposmia Constipation Urgency-urinary dysfunction Erectile dysfunction Orthostatic hypotension Depression Hallucinations EQ5D PSQI
Neurophysiological	RSWA quantification -Visual -Semiautomated
Neuropsychological	Cognitive global assessment (MMSE/MoCA) Neuropsychological evaluation (MCI diagnosis)
Imaging	Neuroimaging (MRI/CT) Spect DAT scan OCT & pupillometry
Laboratory	Skin biopsy Salivary alpha-synuclein Genetic

(MDS)UPDRS-III, (Movement Disorders Society) Unified Parkinson’s Disease Rating Scale Part III; EQ5D, EuroQol Group’s quality of life questionnaire; PSQI, Pittsburg sleep quality index; RSWA, REM sleep without atonia; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; CT, computed tomography; Spect DAT scan, single photon emission computed tomography dopamine transporter scan; OCT, optical coherence tomography